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RESUME: 
Objectif: Les lymphomes épiduraux primaires représentent moins de 10% des tumeurs 
épidurales et de 0,1 à 3,3% de tous les lymphomes. Le but de cette étude a été d'évaluer le 
profil clinique de cette maladie rare, son traitement, ses résultats ainsi que ses facteurs de 
pronostic. 
Matériel et méthode : Entre 1982 et 2002, 52 patients présentant un lymphome épidural 
primaire ont été traités dans neuf institutions membres du Rare Cancer Network. Les critères 
d'inclusion comprenaient : une biopsie confirmant le lymphome non-hodgkinien, un stade IE 
et IIE selon la classification de Ann Arbor, un traitement à visée curative de radiothérapie 
combinée ou non à une chimiothérapie et un suivi d'au moins six mois. Selon la Working 
Formulation, 12 patients (23%) présentaient un lymphome de bas grade, 28 (54%) un grade 
intermédiaire et 12 (23%) un haut grade. Les hommes étaient atteints 1.9 fois plus 
fréquemment que les femmes. L'âge moyen était de 61 ans (intervalle : 21 à 96). Le bilan 
incluait un Ct-scan spinal (98%), une IRM (52%), un CT-scan thoraco-abdominal (77%) et 
une aspiration ou biopsie de moelle osseuse (96%). Les symptômes les plus fréquents 
comprenaient des douleurs dorsales (79% des patients), une faiblesse musculaire (92%) et des 
déficits sensoriels (71 %). Quarante-huit patients ont subi une laminectomie de décompression 
avec résection partielle ou complète (42% et 13% des cas respectivement), tous ont reçu une 
radiothérapie seule (20 patients) ou en combinaison avec une chimiothérapie (32 patients). La 
dose médiane totale était de 36 Gy (intervalle 6-50 Gy) avec une moyenne de 20 Gy par 
fraction (intervalle: 1-25). Le suivi moyen était de 71 mois (intervalle: 22-165 mois). 
Résultats : Suite au traitement, une progression locale a été observée chez 6 patients après un 
temps de latence moyen de 6 mois. Le taux de rechute systémique a été de 42% (22 patients) 
le plus souvent dans les ganglions lymphatiques (n=9) après un intervalle de temps moyen de 
20 mois. Lors du dernier contrôle, 28 patients étaient vivants et 24 patients étaient décédés. 
Le taux de survie à 5 ans, le taux de survie sans maladie et le contrôle local étaient de 69%, 
57% et 88% respectivement. En analyse univariée, les facteurs pronostics favorables 
statistiquement significatifs concernant la survie sans maladie étaient un âge inférieur à 63 
ans, ainsi qu'une réponse neurologique complète. Pour la survie à 5 ans, les facteurs 
favorables étaient un âge inférieur à 63 ans. En analyse multivariée, les facteurs pronostics 
favorables pour la survie globale à 5 ans étaient une réponse neurologique complète, un 
traitement combiné, un volume de radiothérapie plus que focal, une dose totale de 
radiothérapie supérieure à 36 Gy et une résection partielle ou complète de la tumeur. En ce 
qui concerne la survie sans maladie, les facteurs pronostics favorables étaient un âge inférieur 
à 63 ans et un traitement combiné. 
Conclusion : Ce qui ressort de cette analyse est que le bilan diagnostic devrait inclure une 
IRM ou un CT-scan, un échantillon de tissu pour poser le diagnostic pathologique définitif de 
la lésion, une histoire médicale et un examen physique complet, une chimie sanguine, un CT-
scan thoraco-abdominal et une biopsie de la moelle osseuse, un PET-scan devrait également 
faire partie du bilan. Le traitement devrait consister, dans la phase aiguë, en une chirurgie de 
décompression avec ou sans résection, suivie d'une radiothérapie d'au moins 36Gy en 2 Gy 
par fraction et d'une chimiothérapie. Tous les patients présentant un lymphome de haut grade 
ou de grade intermédiaire devraient pouvoir bénéficier d'un traitement combiné. 
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Purposc: To assess the clinical profile, trcatment outcomc, and prognostic factors in primary spinal cpidural 
lymphoma (PSEL). 
Methods and Materials: Between 1982 and 2002, 52 consecutive patients with PSEL were treated in nine 
institutions of the Rare Cancer Network. Forty-eight patients had an Ann Arbor stage IE and four had a stage 
IIE. Forty-eight patients underwent decompressive laminectomy, ail received radiotherapy (RT) with (11 = 32) 
or without chemotherapy (11 = 20). Median RT dose was 36 Gy (range, 6-50 Gy). 
Results: Six (11 % ) patients progressed locally and 22 (42%) had a systemic relapse. At last follow-up, 28 patients 
were alive and 24 had died. The 5-year overall survival, disease-t'ree survival, and local control were 69%, 57%, 
and 88%, respectively. In univariate analyses, favorable prognostic factors were younger age and complete 
neurologie response. Multivariate analysis showed that combined modality treatment, RT volume, total dose 
more than 36 Gy, tumor resection, and complete neurologie response were favorable prognostie factors. 
Conclusions: Primary spinal epiclural lymphoma has distinct clinieal features and outcome, with a relatively good 
prognosis, After therapy, local control is excellent and systemic relapse occurs in less than half the cases. 
Combined modality treatment appears to be superior to RT alone. © 2006 Elsevier lue. 
Primary spinal epidural lymphoma, Non-Hodgkin's lymphoma, Spinal cord compression, Radiation therapy, 
Chemotherapy, Combined modality treatment. 
INTRODUCTION 
The term "primary spinal epidural lymphoma" (PSEL) is 
used to define lymphomas primarily occurring in the epi-
dural space in the absence of other previously detected 
lymphomatous foci. 
Epidural localization is a rare presenting site in non-
Hodgkin 's lymphomas (NHL), and accounts for 1 O<Jo of 
epidural spinal tumors (1) and for 0.1 to 3.3% of ail lym-
phomas (2, 3). Because of the rarity of this entity, we found 
in the literature only retrospective studies including a rela-
tively small number of patients from one institution, or 
single case reports. So far, the largest series has identified 
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Presented in part at the 45th Annual Meeting of the American 
Society for Therapeutic Radiology and Oncology (ASTRO), Salt 
49 patients over 62 years (1907-1969) and was reported by 
Haddad et al. from the Mayo Clinic (4). Apart from this 
unique and relatively large series, most articles have re-
ported small number of patients: Levitt et al. studied 9 cases 
of epidural presentation among 592 patients with NHL (5), 
Epelbaum et al. 10 patients of 453 (6), Goffinet et al. 7 of 
423 (7), and Rudders et al. 2 of 380 (8). Because of the 
limited number of patients and the large timespan, the 
parameters of this disease, such as natural history, prognos-
tic factors, treatment techniques, and survival have been 
difficult to establish. For this reason, and to collect a larger 
number of patients suffering from this type of rare entity, we 
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have established a collaborative, multi-institutional group to 
study rare forms of cancers, the Rare Cancer Network 
(www.rarecancer.net). Thus the purpose of this study was to 
bettcr assess the clinical profile, treatmcnt outcome, and 
prognostic factors in patients strictly staged as IE or IIE 
primary spinal epidural lymphoma. We excluded secondary 
epidural involvement from more advanced NHL from this 
study. 
METHODS AND MATERIALS 
Patients characteristics 
Sixty-two cases of primary spinal epidural lymphoma were 
evaluated and treated in nine member institutions of the Rare 
Cancer Network between 1982 and 2002. Only 52 patients with 
biopsy-proven NHL, with a stage JE or IIE disease according to the 
Ann-Arbor classification (9), with a curative-intent treatment by 
radiotherapy (RT) with or without chemotherapy, and with a 
minimal follow-up of 6 months were included in this study. Thus 
10 patients, 4 with suspicion of infiltration of the bone marrow 
(Stage IV) and 6 with an insufficient follow-up, 3 of whom staged 
as IV, had to be excluded. 
Ali lymphomas in this series were classified according to the 
Working Formulation (10), because it was thought to be the most 
rcproducihle classification when rcclassifying cases includcd in a 
20-year period, and coming from nine different institutions. Thus 
12 patients (23%) had a low-grade, 28 (54%) intermediate-grade, 
and 12 (23%) high-grade NHL. Only th ose patients who were 
strictly staged as JE (11 = 48) or IIE (11 = 4) were selected for the 
study. 
The 52 patients included 36 men (69%) and 16 women (31%), 
with a male-to-female ratio of 2.25. The median age was 61 years 
(range, 21-96 years). The median follow-up was 71 months 
(range, 22-165 months). 
For ail patients, a medical history was taken and physical 
examination was carried out. Staging work-up included a spinal 
computed tomography (CT) scan (98% of patients) and/or mag-
netic resonance imaging (MRI) (52%), whole-body CT scan 
(77%), myelogram (65%), and bone marrow aspiration or biopsy 
(96%). Thirty-six patients had a cerebrospinal fluid examination, 
Table 1. Staging workup in 52 patients with primary spinal 
epidural lymphoma 
Staging workup Il 
Myelogram 34 
Whole-body CT scan 40 
MRI 27 
Spinal CT scan 51 
Cerehrospinal fluid exam 26 
Bone marrow aspiration or biopsy 50 
Gallium scan 14 
LDH 44 
WBC 49 
B2 microglobulin Il 
ESR 21 
Serum protein electrophoresis 23 
% 
65 
77 
52 
98 
50 
96 
27 
84 
94 
21 
40 
44 
Abbreviations: CT = computed tomography; MRI = magnetic 
resonance imaging; LDH = lactate dehydrogenase; WBC = white 
blood cell count; ESR = erythrocyte sedimentation rate. 
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Table 2. Patients' characteristics 
Characteristics Il % 
Gender 
Male 36 69 
Female 16 31 
Symptoms and signs 
Back pain 41 79 
Neck pain 6 li 
Lower limb weakness 46 88 
Upper limb weakness 5 9 
Sensory deficit 37 71 
Sphincter dysfunction 10 19 
Bowel dysfunction 9 17 
Bladder dysfunction 12 23 
Localization 
Thoracic 34 65 
Lumbar 6 li 
Cervical 5 10 
Lurnbo-sacral 2 4 
Cervico-thoracic 2 4 
Thoraco-lumbar 3 6 
Stage 
IE 48 92 
IIE 4 8 
Grade 
Low 12 23 
Intermediate 28 54 
High 12 23 
none of which was positive for the presence of abnormal cells. 
Staging workup for ail patients is shown in detail in Table 1. 
The thoracic region was the most common disease site in 34 
patients (65%). Other sites were lumbar region in 6 patients (11 %), 
cervical in 5 (10%), thoraco-lumbar in 3 (6%), Jumbo-sacral in 2 
(4%), and cervico-thoracic segment in 2 (4%). Regarding the 4 
patients with stage IIE, the thoracic region was involved in 2 
patients, the lumbar and the Jumbo-sacral regions each in 1 patient. 
The most common symptoms were motor weakness (92%), back 
pain (79% ), sensory deficits (71 % ), sphincter dysfunction (19% ), 
bladder dysfunction (23% ), and bowel dysfunction ( 17% ). Two 
patients had unexplained weight Joss and one presented with night 
sweats; otherwise, none of the remaining patients presented with 
"B" symptoms and none had hepatomegaly or splenomegaly. The 
time from the first symptom to the diagnosis varied from 1 day to 
1 year. The patients' characteristics are presented in Table 2. 
Treatment 
Forty-eight patients (92%) underwent a decompressive laminec-
tomy, and partial or complete resection was performed in 22 cases 
(42%) and in 7 cases (13%), respectively. Ali patients received RT, 
either alone (11 = 20) or combined with chemotherapy (11 = 32). 
Fourteen patients underwent RT before chemotherapy, 16 under-
went chemotherapy before RT, one had a "sandwich" modality, 
and 1 had a concomitant treatment. 
Radiotherapy 
The median RT dose was 36 Gy (range, 6-50 Gy) in a median 
20 fractions (range, 1-25 fractions). Ten patients had a focal 
treatment (i.e., a treatment focused only on the vertebral segment 
with the lymphomatous lesion), whereas the remaining 42 received 
more than focal treatment: 1 patient was treated on 17 vertebral 
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bodies, l on 13, 2 on 12, 4 on 10, 3 on 8, 8 on 7, 9 on 6, 11 on 5, 
2 on 4, and 1 patient on 3 vertebral bodies. In 31 cases, the RT 
technique included one posterior field, the remainder having two or 
more converging beams. 
Chemorherapy 
Thirty-two of the 52 patients (61 %) had chemotherapy. For 18 
of them, chemotherapy consisted of cyclophosphamide, doxorubi-
ein, vincristine, and prednisone, with 11 receiving six cycles, 1 
rccciving five cycles, 3 receiving four cycles, 2 receiving threc 
cycles, and 1 recciving one cycle. Two patients receivcd cyclo-
phosphamide, epiruhicin, vincristine, and prednisone, 1 for six 
cycles and l for three cycles. Four patients received a combination 
of bleomycin, Adriamycin, cyclophosphamide, vincristine, and 
prednisone, with 2 receiving three cycles, and 2 receiving one 
cycle. Two patients had melhotrexate, doxorubicin, cyclophosph-
amide, vincristine, prednisone, and bleomycin in three cycles. One 
rcccived cyclophosphamide, vincristine, and prcdnisone in six 
cycles. Three patients received a combination of prednisone, doxo-
rubicin, cyclophosphamide. etoposide, cytarabine, bleomycin, vin-
cristine, methotrexate, and leucovorin, 1 in eight cycles and 2 in 
six cycles. One patient received epirubicin, vincristine, etoposide, 
~yclophosphamicle, and prednisone for six cycles. In 1 patient, the 
type of chemotherapy could not be found. Intrathecal methotrexate 
was administered in 10 patients. 
Chemotherapy according to age, grade, and srage 
Of the 25 patients older than 63 years, 13 (52%) received 
chemotherapy versus 19 of 27 (70%) of patients younger than 63 
years. With regard to grade, 3 of 12 (25%) with low grade, 19 of 
28 (68%) with intermediate grade, and 10 of 12 (83%) with high 
grade had chemotherapy. Ali 4 patients with stage IIE were treated 
with chemotherapy versus 28 of 48 (58%) with stage IE. 
Statistical analysis 
Disease-free survival (DFS), overall survival (OS), and local 
control wcrc calculated from the date of biopsy using the Kaplan-
Meier method (11). The events were death (including ail causes of 
death) for OS, death (including ail causes of death) or relapse for 
DFS, and local relapse for local control. Differences between 
groups were assessed using the log-rank test (12). We screened for 
independent prognostic factors with a Cox regression analysis 
(13). A p value of <0.05 was considered statistically significant. 
Neurologie response was defined as ( 1) complete neurologie 
response (i.e., eomplete recovery of any motor deficit from PSEL); 
(2) partial neurologie response when there was incomplete motor 
recovery; or ( 3) no response if there was no motor recovery after 
treatment. 
RESULTS 
Response rate, local control, and systemic relapse 
Of the 48 patients who presented initially with motor 
weakness, 12 (25%) had a complete neurologie response 
and 36 (75%) had a partial neurologie response. Local 
progression was observed in 6 patients at 5.2, 5.5, 5.7, 6, 43, 
and 92 months, respectively, after the initial diagnosis. The 
median time to local relapse was 6 months with a local 
control rate of 88%. 
Systemic relapses were observed in 22 patients (42%) after 
a median latency period of 20 months. Those were mainly 
in lymph nodes (n = 9), chest or abdomen (n = 5), bone 
marrow (n = 4), and the central nervous system (CNS) (n = 
4). The characteristics of patients with CNS relapse, their 
second treatment, and outcome are presented in Table 3. 
Survival 
The 5-year OS, DFS, and local control were 69%, 57%, 
and 88% respectively (Fig. 1). Eighteen patients <lied from 
their lymphoma and 6 from other causes (2 from esophageal 
cancer, 1 from colon cancer, 1 from cerebral hemorrhage, 1 
from a ruptured aneurysm, and 1 from sepsis). 
Prognostic factors 
Univariate analyses revealed that younger age ( <63 
years) and complete neurologie response were statistically 
significant favorable prognostic factors for DFS, whercas 
Table 3. Characteristics of patients with CNS relapse 
Patient 1 Patient 2 Patient 3 Patient 4 
Sex M M F M 
Age 69 66 56 67 
Grade Intermediate Righ Intermediate Intermediate 
Stage IEA IEA IEA IEA 
Initial localization Thoracic spine Thoracic spine Thoracic spine Thoracic-lumbar spine 
Initial treatment RT + BACOP RT alone RT + ProMACE/ RT alone 
CytaBOM 
"Prophylactic" IT MTX None None None None 
Localization at recurrence Subarachnoid spread Suparachnoid spread Subarachnoid spread Subarachnoid spread and 
cranial nerve involvement 
Treatment at recurrence Ara-C, etoposide, Patient refused CROP Cranial RT, IT MTX, 
ITMTX treatment chemotherapy (unspecified) 
Outcome D+D D+D D+D D+D 
Abbreviations: M = male; F = female; CSF = cerebrospinal fluid; IT MTX = intrathecal methotrexate; D+ D = dead with disease; 
BACOP = bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone; CNS = central nervous system; RT = radiotherapy; 
CROP = cyclophosphamide, doxorubicin, prednisone, vincristine; ProMACE/CytaBOM = bleomycin, cyclophosphamide, cytarabine, 
doxorubicin, etoposide, leucovorin, methotrexate, prednisone, vincristine; Ara-C = cytarabine. 
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Fig. l. Overall survival (OS), disease-free survival (DFS), and 
local contrai in 52 patients with primary spinal epidural lym-
phoma. 
combined modality treatment conferred an advantage of 
borderline insignificance. For OS, only age proved lo be 
significant (Table 4). 
In multivariate analysis, the favorable independent prog-
nostic factors influencing OS were complete neurologie 
response, combined modality treatment, RT volume more 
than focal, total RT dose more than 36 Gy, and complete or 
Table 4. Univariate analysis (log-rank test) 
Ali patients 
Age (years) 
<63 
>63 
Sex 
M 
F 
Stage 
IE 
IIE 
Grade 
Low 
Intermediate/high 
LDH 
Ab normal 
Normal/not done 
Treatment 
RT alone 
Combined 
treatment 
RT volume 
Focal 
More than focal 
Neurologie response 
CR 
PR 
Il 
52 
27 
25 
36 
16 
48 
4 
16 
36 
Il 
41 
20 
32 
10 
42 
13 
35 
5-year 
os(%) 
69 
88 
50 
69 
61 
66 
100 
65 
70 
90 
86 
60 
75 
100 
84 
85 
62 
p 5-year p 
value DFS (%) value 
0.001 
NS 
NS 
NS 
NS 
NS 
NS 
0.09 
57 
76 
33 
57 
50 
58 
25 
50 
53 
38 
55 
40 
61 
38 
55 
78 
45 
0.001 
NS 
NS 
NS 
NS 
0.07 
NS 
0.02 
Abhreviations: OS = ovcrall survival; DFS = disease-frce 
survival; NS = not significanl; CR = complete neurologie re-
sponse; PR = partial neurologie response; M = male; F = female; 
RT = radiothcrapy; LDH = lactic dehydrogcnase. 
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Table 5. Multivariate analysis (Cox model) 
Factor 
Combined treatment 
Neurologie response 
Age <63 years 
RT volume more than focal 
RT dose more lhan 36 Gy 
Resection of the tumor mass 
OS (p value) 
0.005 
0.001 
NS 
0.001 
0.01 
0.004 
DFS (p value) 
0.02 
NS 
0.006 
NS 
NS 
NS 
Abbreviations: OS = overall survival; DFS = disease-free 
survival; NS = not significant; RT = radiotherapy. 
partial lymphoma resection; those influeneing DFS were 
age younger than 63 years of age and combined modality 
treatment (Table 5). 
It is quite likely that neurologie response reflected tumor 
response. Unfortunately, because of the retrospective nature 
of this analysis, a re!iable assessment of the tumor response 
could not be obtained in most patients, in contrast to the 
neurologie status and response, which were well recorded. 
Acute side effects 
Four patients (8%) presented with Grade 1 skin reactions; 
3 (6%) had Grade 2 and 1 (2%) Grade 3 oropharyngeal 
mucositis, whereas 4 patients had Grade 2 esophagitis. Two 
patients complained of fatigue, 4 of nausea and vomiting, 3 
of diarrhea-all of the latter effects were Grade 1 or 2. One 
patient suffered from left foot dysesthesia and 1 from lower 
back and leg pains. One patient showed a very strange 
disease course with acute colitis associated with Guillain-
B arré syndrome; radiotherapy had to be interrupted after 18 
of the 22 fractions planned and the patient was hospitalized 
for 3 months, 1 month of which was in intensive care. 
DISCUSSION 
Our series, collected in nine institutions of the Rare 
Cancer Network, is the largest of PSEL, with 52 patients 
treated over a 20-year period. The second largest, from the 
Mayo Clinic, was reported on 49 patients; however, the 
observation period spanned 62 years and predated the era of 
modern radiotherapy and chemotherapy (4). 
Patient characteristics, symptoms, and signs 
In our study, 46 of the 52 patients (88%) were older than 
age 40 years, which is comparable to the 80-82% reported 
by others (4, 6). Although PSEL has been described in 
pediatric patients (14--16), this disease predominantly af-
fects older people with a median age of 55 to 65 years 
(17-19). In our series, the median age was 61.5 years. The 
male preponderance with 69% is comparable to that of other 
authors (i.e., between 60-76%) (4, 6, 20). 
In the present experience, the symptoms and signs were 
those to be expected with any epidural tumor located in the 
spinal canal, namely varying degrees of upper or lower limb 
weakness (92%) and back (79%) or neck pain (11 %). In 
Primary Spinal epidùral lymphon\a • V. MONNARD et al. 5 
addition, varying sensory deficits (69%) and impairment of 
bladder (23%) or bowel (l 7%) fonctions were seen. This 
corresponds to the symptoms and signs reported by others: 
Salvati et al. reported 100% of back pain and 89% of motor 
impairment (2); Cappellani et al. reported 70% of back pain 
(20). Lymphoma is a disease which can be accompanied 
with "B" symptoms, such as weight Joss, night sweats, and 
fever. However, patients who present with a clinical Stage I, 
as is the case in 92% of our patients, or Stage Il (8% in our 
series) are usually free of systemic manifestations. In our 
study, only 2 patients presented with unexplained weight 
Joss and l patient presented with night sweats. The area of 
involvement was mainly in the thoracic segment. Sixty-five 
percent of the cases in our study were localized in this 
portion of the spine. This finding is in agreement with those 
of other authors such as Di Marco et al. and Love et al., who 
observed it in 78% and 64% of their cases, respectively (21, 
22). However in other studies, the area of involvement was 
almost equally distributed between the thoracic and the 
lumbar portions (23, 24). Epelbaum reported that none of 
their patients had a cervical spine involvement (6) and 
others revealed that cervical involvement was the least 
common (2, 23, 25). ln our series, 10% of the patients had 
a cervical location of the tumor mass, which was the third 
most commonly affected area. 
Diagnostic workup 
For ail patients, a medical history was taken and phys-
ical examination was carried out. Ninety-eight percent of 
our patients underwent a spinal CT scan and 52% had an 
MRI. Even if MRI is the standard imaging procedure for 
spinal lesions and has now replaced myelography, still, 34 
of our 52 patients diagnosed between 1982 and 2002 un-
derwent a myelogram, but mainly in the earlier period. In 
1986, Epelbaum et al. described myelography as "the most 
reliable procedure for the investigation and localization of 
cord tumors as it usually revealed a complete block to the 
ftow contrast media" (6). In the series of Rathmell et al., the 
clinical diagnosis of extradural compression was confirmed 
by myelography for 20 of their 22 patients (19), whereas in 
the series of Cappellani et al., a myelography was per-
formed for ail patients (20). Most of our patients had a 
complete systemic workup for lymphoma: whole-body CT 
scan was done in 77% of cases, bone marrow assessment 
(aspiration or biopsy) in 96%, cerebrospinal lluid examina-
tion in 50%, lactic dehydrogenase measured in 84%, and 
white blood cell count in 94%. 
Treatment 
Surgery. ln our study, 48 patients (92%) underwent a 
decompressive laminectomy. Partial resection was per-
formed in 22 cases (42%) and complete resection in 7 cases 
(1:'1%). Traditionally, surgery is the first therapeutic ap-
proach in malignancies compressing the spinal cord. Be-
cause lymphomas are very chemo- and radiosensitive tu-
mors, the indications for surgery have been reduced and 
limited to laminectomy or even biopsy only, leaving the 
major role to RT and chemotherapy (6, 17). However, 
especially because the tumor type is unknown at the time of 
initial presentation, decompression, and, in some instances, 
partial removal of the tumor mass may represent a good 
option. lt immediately alleviates the spinal cord compres-
sion while establishing the correct histologie diagnosis. 
Radiation therapy. All patients in our series underwent 
radiation therapy and for 20 of them, RT was given alone. 
The median RT dose was 36 Gy (range, 6-50 Gy). Radia-
tion doses employed by various authors vary widely, with 
ranges between 20 and 60 Gy (4, 24), and doses of at least 
25 Gy are recommended (18, 23). lt appears though from 
our multivariate analysis that a dose of at least 36 Gy at 2 
Gy per fraction or its equivalent should be considered. 
Our data suggest that a radiation volume more than focal 
secmed to influence the outcomc. As many authors advise 
extending the field of irradiation to two or three vertebral 
segments both above and below the tumor site, and some-
times laterally to include the mediastinal and retroperitoneal 
lymph nodes, we would agree that in epidural lymphoma, 
the use of relatively large volumes seems to be appropriate. 
Chemotherapy. Sixty-one percent of patients underwent 
chemotherapy; 14 received it after RT, 16 before RT, 1 had 
a "sandwich" modality treatment, and 1 a concomitant treat-
ment. No patient received chemotherapy alone. Although 
Oviatt et al. reported on 2 patients with epidural compres-
sion secondary to NHL who were successfully treated by 
chemotherapy alone (26), most authors have opted for a 
treatment based on surgery followed by radiation therapy (2, 
4, 6, 18, 19, 25). 
Combined modality treatment. Our multicentric study 
suggests that combined modality treatment, including RT 
and chemotherapy, seems to be the most efficient treatment 
for primary spinal epidural lymphoma, with a local control 
of 88% and a 5-year overall survival of 69%. Di Marco et 
al. observed 9 patients with PSEL and reported a long-term 
survival for 2 of them. Those 2 long-term survivors were 
those who received a complete chemotherapeutic course 
after RT (21). Epelbaum et al. with intensive therapy, using 
RT and combination chemotherapy, achieved an actuarial 
5-year survival rate of 66% (6). Rathmell et al. reported a 
significant difference between patients treated with radia-
tion therapy alone and those with combined modality with 
an overall actuarial survival of 33% and 86%, respectively 
(19). In our series, among the 20 patients who received RT 
alone, 11 suffered a systemic relapse, from which 7 died, 2 
are still alive with disease 4 and 9 years after the end of the 
initial treatment, and 2 are alive without disease 4 and 15 
years, respectively, after treatment. ln addition, of those 
patients treated with RT alone, 1 had a local relapse and 
died 8 months after the end of the treatment. Among the 32 
patients who received a combined modality treatment, 19 
(59%) are still alive without disease 2-13 years after the 
treatment, 8 had a systemic relapse, and 5 a local relapse. In 
multivariate analysis, combined modality treatment was su-
perior to RT alone (p = 0.01). 
Central nervous system prophylaxis. Mackintosh et al. 
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(27) have made an analysis of CNS involvement in lym-
phoma, which showed a significantly increased risk of CNS 
relapse for patients with extradural disease. However, as 
the majority of the patients had disseminated lymphoma in 
their series, it is not certain whether patients with localized 
disease carry the same risk. In our series, CNS prophylaxis 
by intrathecal therapy with methotrexate was given in 10 
patients (19% ), whereas another 4 received intrathecal che-
motherapy in combination with systemic treatment for re-
lapse. Of the latter, none had received prophylactic intra-
thecal chemotherapy during initial treatment. 
Neurologie outcome and general prognosis 
In our series, a complete neurologie response was observed 
in 12 of the 48 patients (25%) who presented initially with 
motor weakness. Even if it can take several months to achieve 
a complete recovery, complete neurologie response was the 
most significant favorable prognostic factor in the multivariate 
analysis with regard to OS (p = 0.001). Eeles et al. and 
Rathmell et al. in their series also found that the outcome 
depends on the neurologie status after treatment (19, 25). 
Overall prognosis 
With regard to the outcome of patients with PSEL, over-
all prognosis was relatively good: 25 patients are alive 
without disease 2-17 years after the treatment, 3 are alive 
with disease after 4-9 years, 6 died without disease 10-89 
months after treatment, and 18 died with disease 6-121 
months after treatment. Similar findings have also been 
made by others (4, 6, 22, 23). 
Local contra{ 
The local control rate in this series was 88%; after ther-
apy, 6 patients (11%) progressed locally. ln their series, 
Rathmell et al. found also an excellent local control of 88% 
at 10 years, with only 2 patients failing to achieve a per-
manent local control (19). Only 1 of their 12 patients treated 
with RT alone relapsed within the radiation field, 10 months 
after treatment ( 19). Another patient had a residual 
paraspinal mass on X-ray and developed clinical evidence 
of recurrent spinal cord compression, as well as generalized 
disease. A further 7 patients, ail treated with RT alone, 
relapsed at distant sites, mainly in the CNS and lymph 
nodes, without local failure. 
Systemic relapse 
Twenty-two patients (42%) suffered from a systemic re-
lapse, mainly in the lymph nodes (11 = 9), chest or abdomen 
(11 = 5), bone marrow (n = 4), and CNS (11 = 4). Of these, 
14 died with disease, 1 died without disease, 3 are alive with 
disease, and 4 are alive and free of disease. Among the 10 
patients of Epelbaum et al. (6) with spinal cord presentation 
of NHL, 7 achieved a complete remission after initial treat-
ment. Four of them treated by combined modality treatment 
relapsed after a median time of 15 months, with relapses in 
the bone, the bone marrow, the CNS, and the mediastinum. 
The other 3 remained free of disease, whereas in the last 3 
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patients, the disease progressed while the patients were on 
initial treatment. 
Prognostic factors 
As was shown in other studies of the Rare Cancer Net-
work, the larger collection of data in rare cancers enabled us 
to attempt to define pre-therapeutic and therapeutic prog-
nostic factors. For example, in our study we determined that 
sex did not influence the prognosis, but that age did have an 
impact as univariate analyses with a significant survival and 
DFS advantage for patients aged Jess than 63 years (p = 
0.001 and 0.006 respectively). However, it should be noted 
that younger patients tended to be treated more aggressively 
both with radiation therapy and chemotherapy because, 
among the 27 patients who were younger than 63 years old, 
19 (70%) received a combined modality treatment versus 13 
(52%) of 25 patients older than 63 years. 
Concerning the treatment, we found that a radiotherapy 
volume more than focal, and the total radiotherapy dose 
(>36 Gy) and combined modality therapy influenced over-
all survival (p = 0.001, 0.01, and 0.005, respectively), by 
multivariate analysis. Regarding the tumor grade, patients 
with high or intermediate grade NHL were not treated 
differently since 68% and 83% of patients with respectively, 
intermediate- and high-grade PSEL, received a combined 
modality treatment. However, only 25% of patients with 
low-grade NHL received combined modality treatment. Al-
together however, grade did not seem to influence the prog-
nosis. 
CONCLUSION 
Spinal epidural lymphoma is obviously a very rare entity 
and for this reason we should be very cautious in drawing 
too finn conclusions, especially with regard to therapy. 
However, because we have analyzed one of the largest groups 
of patients with PSEL, we would like to propose some 
diagnostic and therapeutic standards, based on our data. 
1. Diagnostic workup should include in the acute phase an 
MRI (or if not available, a CT scan) of the entire spine 
and tissue sampling during the emergency surgery for a 
definitive pathologie diagnosis. Elective workup should 
consist of a complete medical history and physical ex-
amination, full blood counts, blood chemistry including 
serum electrophoresis, CSF examination, whole-body 
CT scan or MRI, and bone marrow biopsy or aspira-
tion. Although no patient in our series underwent a 
positron emission tomography or positron emission 
tomography-CT scan, this examination should probably 
be part of the workup in the future. 
2. Treatment will almost always include in the acute phase 
some form of emergency decompressive surgery, with 
or without resection, followed by RT and chemotherapy. 
RT plays a central role and should be given to a volume 
encompassing the epidural mass, with two to three ver-
tebral bodies above and below the lesion at a dose 
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of at least 36 Gy at 2 Gy pcr fraction or its equivalent. 
Chemotherapy should almost always be adcled to RT, 
using four to six cycles of cyclophosphamicle, doxoru-
bicin, vincristine, and prednisone or cyclophosphamide, 
doxorubicin, vincristine, and preclnisone-like regimes, 
especially in high- or intermediate-grade PSEL. 
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